Minerva Neurosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Inderjit Kaul, a Director of Minerva Neurosciences, Inc., received 12,147 shares of common stock on August 3, 2026.
NASDAQ
Frederick W. Ahlholm, SVP and CFO of Minerva Neurosciences, was granted 680,000 employee stock options.
NASDAQ
CEO Remy Luthringer was granted 1,690,700 employee stock options in Minerva Neurosciences, Inc. as part of a long-term incentive plan.
NASDAQ
Director Fouzia Laghrissi-Thode was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of a standard equity incentive.
NASDAQ
Minerva Neurosciences director David Kupfer was granted 50,000 stock options as part of his non-employee director compensation.
NASDAQ
Director Inderjit Kaul was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of a standard equity compensation package.
NASDAQ
Minerva Neurosciences director G. Jan van Heek was granted 50,000 stock options as part of his non-employee director compensation.
NASDAQ
Director Hans Peter Hasler was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of his compensation.
NASDAQ
Chief Business Officer and General Counsel James Joseph O'Connor was granted 350,800 employee stock options in Minerva Neurosciences.
NASDAQ
Minerva Neurosciences director David Kupfer was granted 50,000 stock options with an exercise price of $3.98, vesting quarterly over one year.
NASDAQ
Minerva Neurosciences Director Inderjit Kaul was granted 364,504 stock options with vesting tied to clinical trial milestones.
NASDAQ
Minerva Neurosciences director Hans Peter Hasler was granted 50,000 stock options with an exercise price of $3.98, vesting quarterly over one year.
NASDAQ
Minerva Neurosciences director G. Jan Van Heek was granted 50,000 stock options with an exercise price of $3.98, vesting quarterly over one year.
NASDAQ
Minerva Neurosciences director Fouzia Laghrissi-Thode was granted 50,000 stock options with a $3.98 exercise price, vesting quarterly over one year.
NASDAQ
Minerva Neurosciences' SVP, CFO, and Secretary, Frederick W. Ahlholm, was granted 500,000 employee stock options with an exercise price of $3.98 per share.
NASDAQ
Minerva Neurosciences, Inc. President Geoff Race was granted 1.5 million employee stock options with an exercise price of $3.98, vesting over four years.
NASDAQ
Minerva Neurosciences CEO Remy Luthringer was granted 2.25 million employee stock options with an exercise price of $3.98, vesting over four years.
NASDAQ
Minerva Neurosciences director Inderjit Kaul received 9,500 stock options at a $4.11 strike, vesting quarterly over three years.
NASDAQ
Director G Jan Van Heek acquired 12,500 stock options in Minerva Neurosciences, Inc. as part of the company's compensation program for non-employee directors.
NASDAQ
A director of Minerva Neurosciences, Inc. was granted stock options to purchase 12,500 shares of common stock.
NASDAQ
David Kupfer, a director at Minerva Neurosciences, acquired 12,500 stock options as part of the company's non-employee director compensation program.
NASDAQ
A director of Minerva Neurosciences, Inc. acquired stock options for 12,500 shares of common stock.
NASDAQ
Frederick W. Ahlholm, SVP, CFO and Secretary of Minerva Neurosciences, Inc., was granted 47,500 stock options on December 5, 2024.
NASDAQ
Minerva Neurosciences' President, Geoff Race, acquired 95,000 stock options on December 5, 2024, according to a recent SEC filing.
NASDAQ
Minerva Neurosciences CEO, Remy Luthringer, was granted 105,000 employee stock options on December 5, 2024.